Wyeth/ViroPharma Discontinue Study Of Hep C Drug Due To Elevated Liver Enzymes
This article was originally published in The Pink Sheet Daily
Executive Summary
After Phase II safety signal, next steps for HCV-796 may be lower treatment dose or shorter treatment duration.
You may also be interested in...
Roche Licenses Metabasis Liver Technology, Collaborates To Develop HCV Drugs
HepDirect allows more potent concentrations of nucleosides in liver, resulting in lower dose requirement.
Roche Licenses Metabasis Liver Technology, Collaborates To Develop HCV Drugs
HepDirect allows more potent concentrations of nucleosides in liver, resulting in lower dose requirement.
Wyeth Halts Alzheimer’s Trial, Drops HCV Candidate
With partner Elan, company halts ACC-001 Phase II trials after report of skin lesions.